Search

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

… Monday, December 1, 2014 Summary Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture. Since the late 1990s, when researchers first reported a technique to isolate and grow human embryonic stem cells, known as ES cells, in culture

Learn about diversity and inclusion at Memorial Sloan Kettering, as people from across MSK share their insights and personal experiences.

… Thursday, October 1, 2020 Memorial Sloan Kettering is committed to having conversations about discrimination, diversity, and inclusion, and creating change. People from across MSK share their personal experiences and insights. Louis Voigt Louis Voigt LOUIS VOIGT Associate Attending Department of Anesthesiology

The results of a large, international randomized trial herald a change in medical practice for the treatment of melanoma.

… Thursday, June 8, 2017 Summary A large study of nearly 2,000 people has answered an important question about the surgical treatment of melanoma , a type of skin cancer. For people with cancer detected in their sentinel lymph node, a watch-and-wait approach rather than immediate removal of all regional

GSK’s Fourth Biennial Retreat on May 6 and 7 at the Mohonk Mountain House in New Paltz, New York, will feature former Sloan Kettering Institute Director Dr. Thomas J. Kelly.

… Monday, May 2, 2016 The Gerstner Sloan Kettering Graduate School of Biomedical Sciences’ fourth Biennial Retreat will take place from May 6 through May 7, 2016, at the Mohonk Mountain House in New Paltz, New York. The retreat will celebrate the first decade of matriculants in GSK’s graduate program.

Memorial Sloan Kettering Cancer Center announced it has selected Epic to provide a new platform for integrated care that will ensure patients and physicians can more easily access electronic health records.

… Monday, November 21, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced it has selected Epic to provide a new platform for integrated care that will ensure patients and physicians can more easily access electronic health records (EHR). Implementing Epic is an important milestone that will

Memorial Sloan Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2-positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin®), a drug previously shown to improve outcomes in advanced cancer and prevent the return of cancer in women diagnosed with higher-risk, early-stage, HER2-positive breast cancer. This study appears online in the journal Cancer, and will be published in a future print edition.

… Friday, June 24, 2011 Memorial Sloan Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2 -positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin ® ), a drug previously shown to improve outcomes in advanced

Learn how MSK’s Antibiotic Management Program is leading the way in ensuring that antibiotics and other antimicrobial drugs are used responsibly.

… Wednesday, May 22, 2019 Summary In this Q & A, infectious disease expert Susan Seo discusses MSK’s Antibiotic Management Program. It ensures that antibiotics and other antimicrobial drugs are used responsibly. The rapid emergence of drug-resistant microorganisms is “a global crisis that threatens a century

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2024 Marie-Josée Kravis Women in Science Endeavor (Kravis WISE) fellowship grant recipients.

… Thursday, February 29, 2024 Each year, the Marie-Josée Kravis Women in Science Endeavor (WISE) initiative awards several fellowships to female graduate students and postdoctoral fellows to support their research at Memorial Sloan Kettering Cancer Center (MSK). The awards are announced in March, to coincide

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.

… Thursday, October 28, 2010 An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer . The study was published today online in the open-access journal

GSK congratulates ten of its doctoral students who have been recognized by esteemed organizations for their promising academic research.

… Thursday, October 8, 2020 The Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences congratulates ten of its doctoral students — eight of them women — who have been recognized by esteemed organizations for their promising academic research. They each will receive stipend awards to support